Finance

Beta
Lists
IMM:ASX
Immutep Ltd
A$0.050
-1.96%
(-0.00100) 1D
Jun 4, 4:17:03 PM GMT+10  ·   AUD
All symbols
SymbolPriceChange% Change
Generating top insights for IMM...
Open
A$0.05
High
A$0.05
Low
A$0.05
Mkt. cap
73.69M
Avg. vol.
27.25M
Volume
68.82M
52-wk high
A$0.47
52-wk low
A$0.03
EPS
-A$0.06
Shares outstanding
1.47B
No. of employees
19
Open
A$0.05
High
A$0.05
Low
A$0.05
Mkt. cap
73.69M
Avg. vol.
27.25M
Volume
68.82M
52-wk high
A$0.47
52-wk low
A$0.03
EPS
-A$0.06
Shares outstanding
1.47B
No. of employees
19
Analyst outlook
Analyst Ratings
Based on 3 analysts giving stock ratings to IMM in the past 3 months
Buy
Buy
1
Hold
2
Sell
0
12 month forecast
Based on 3 Wall Street analysts offering 12 month price targets for IMM in the last 3 months.
Highest
Current A$0.05
A$0.40 (+705.40%)
Average
A$0.17 (+236.59%)
Lowest
A$0.04 (-19.46%)
News stories
From sources across the web
Profile
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech. Prima currently has three main products in its pipeline, all acquired with Immutep: Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer. IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline. IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis. Wikipedia
About Immutep Ltd
CEOMarc Voigt
Employees19
Founded2001
Headquarters-
SectorBiotechnology
Websiteimmutep.com
Last report
Jan 29, 2026
Fiscal period
Q2 2026
EPS / Est. (AUD)
- / -
Revenue / Est. (AUD)
3.01M / -
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in AUD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in AUD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
948.05K
948.05K
3.01M
3.01M
Cost of goods sold
18.04M
18.04M
23.31M
23.31M
Cost of revenue
18.04M
18.04M
23.31M
23.31M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.21M
2.21M
2.71M
2.71M
Operating expense
2.21M
2.21M
2.71M
2.71M
Total operating expenses
20.25M
20.25M
26.03M
26.03M
Operating income
-19.30M
-19.30M
-23.01M
-23.01M
Other non operating income
195.00
195.00
-256.17K
-256.17K
EBT including unusual items
-19.53M
-19.53M
-22.43M
-22.43M
EBT excluding unusual items
-19.49M
-19.49M
-22.42M
-22.42M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-19.53M
-19.53M
-22.43M
-22.43M
Net profit margin
-2,059.84%
-2,059.84%
-744.36%
-744.36%
Earnings per share
-
-
-
-
Interest and investment income
1.08M
1.08M
798.85K
798.85K
Interest expense
-9.90K
-9.90K
-9.65K
-9.65K
Net interest expenses
1.07M
1.07M
789.20K
789.20K
Depreciation and amortization charges
-
-
-
-
EBITDA
-18.75M
-18.75M
-22.45M
-22.45M
Gain or loss from assets sale
593.00
593.00
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer